blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3124035

EP3124035 - NOVEL CANCER ANTIGEN EEF2 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.02.2020
Database last updated on 28.05.2024
FormerThe patent has been granted
Status updated on  15.03.2019
FormerGrant of patent is intended
Status updated on  08.03.2019
FormerExamination is in progress
Status updated on  15.02.2019
FormerGrant of patent is intended
Status updated on  27.09.2018
FormerExamination is in progress
Status updated on  19.01.2018
FormerRequest for examination was made
Status updated on  28.07.2017
FormerThe application has been published
Status updated on  30.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
International Institute of Cancer Immunology, Inc.
13-9, Enoki-cho
Suita-shi, Osaka 564-0053 / JP
[2017/05]
Inventor(s)01 / Sugiyama, Haruo
2-19-30, Senbanishi
Minoo-shi Osaka 562-0036 / JP
02 / Oji, Yusuke
1-5-24, Tamai-cho
Toyonaka-shi, Osaka 560-0026 / JP
 [2019/12]
Former [2017/05]01 / Sugiyama, Haruo
2-19-30, Senbanishi
Minoo-shi Osaka 562-0036 / JP
02 / Oji, Yusuke
1-3-4-503, Shinkitano
Yodogawa-ku
Osaka-shi Osaka 532-0025 / JP
Representative(s)dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
[2017/05]
Application number, filing date16188901.908.01.2010
[2017/05]
Priority number, dateJP2009000260808.01.2009         Original published format: JP 2009002608
[2017/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3124035
Date:01.02.2017
Language:EN
[2017/05]
Type: B1 Patent specification 
No.:EP3124035
Date:17.04.2019
Language:EN
[2019/16]
Search report(s)(Supplementary) European search report - dispatched on:EP20.12.2016
ClassificationIPC:A61K38/04, A61K38/08, C07K14/82, C07K7/06
[2017/05]
CPC:
A61K31/713 (EP,US); A61K39/0011 (EP,US); A61K38/08 (EP,US);
A61P35/00 (EP); A61P43/00 (EP); C07K14/47 (EP,US);
C07K14/82 (EP,US); C12N15/113 (EP,US); C12N15/1135 (EP,US);
C12Q1/6886 (EP,US); G01N33/57484 (EP,US); A61K38/00 (EP,US);
C12N2310/11 (EP,US); C12N2310/14 (EP,US); C12N2310/531 (EP,US);
C12Q2600/118 (EP,US); C12Q2600/158 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2017/35]
Former [2017/05]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:NEUARTIGES TUMORANTIGEN EEF2[2017/05]
English:NOVEL CANCER ANTIGEN EEF2[2017/05]
French:NOUVEL ANTIGÈNE DE CANCER EEF2[2017/05]
Examination procedure15.09.2016Date on which the examining division has become responsible
24.07.2017Amendment by applicant (claims and/or description)
24.07.2017Examination requested  [2017/35]
18.01.2018Despatch of a communication from the examining division (Time limit: M04)
11.05.2018Reply to a communication from the examining division
28.09.2018Communication of intention to grant the patent
07.02.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
07.02.2019Fee for grant paid
07.02.2019Fee for publishing/printing paid
07.03.2019Information about intention to grant a patent
07.03.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10729253.4  / EP2386633
EP13188341.5  / EP2684568
Opposition(s)20.01.2020No opposition filed within time limit [2020/13]
Fees paidRenewal fee
15.09.2016Renewal fee patent year 03
15.09.2016Renewal fee patent year 04
15.09.2016Renewal fee patent year 05
15.09.2016Renewal fee patent year 06
15.09.2016Renewal fee patent year 07
30.01.2017Renewal fee patent year 08
30.01.2018Renewal fee patent year 09
29.01.2019Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.01.2010
AT17.04.2019
CY17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
MK17.04.2019
MT17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
IE08.01.2020
LU08.01.2020
[2022/32]
Former [2022/28]HU08.01.2010
AT17.04.2019
CY17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
MT17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
IE08.01.2020
LU08.01.2020
Former [2021/08]AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
IE08.01.2020
LU08.01.2020
Former [2020/46]AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
LU08.01.2020
Former [2020/39]AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/26]AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/17]AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/14]AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SK17.04.2019
SM17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/11]AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
SK17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/10]AT17.04.2019
CZ17.04.2019
DK17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/09]CZ17.04.2019
DK17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/04]FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2019/52]FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
PT17.08.2019
Former [2019/51]FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
PT17.08.2019
Former [2019/50]FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
SE17.04.2019
NO17.07.2019
GR18.07.2019
PT17.08.2019
Former [2019/49]FI17.04.2019
HR17.04.2019
LT17.04.2019
NL17.04.2019
SE17.04.2019
NO17.07.2019
PT17.08.2019
Former [2019/48]FI17.04.2019
LT17.04.2019
NL17.04.2019
SE17.04.2019
NO17.07.2019
PT17.08.2019
Former [2019/47]FI17.04.2019
LT17.04.2019
NL17.04.2019
NO17.07.2019
Former [2019/44]NL17.04.2019
Documents cited:Search[A]WO02094981  (TECHNION RES & DEV FOUNDATION [IL], et al) [A] 1-5 * page 47, line 25 - page 49, line 2; sequence 92 * * page 69, line 18 - line 22 * * page 36, line 26 - line 28 *;
 [A]WO03106616  (GAVISH GALILEE BIO APPL LTD [IL], et al) [A] 1-5 * page 15, line 5 - line 18; claims 15,16 ** page 16, line 5 - line 7 *;
 [A]WO2005011730  (QUEEN MARY & WESTFIELD COLLEGE [GB], et al) [A] 1-5 * claims 1-31; table 4 *;
 [X]EP1536009  (SUGIYAMA HARUO [JP], et al) [X] 1-5 * examples 1-6; claims 1-25 *;
 [A]  - HOGAN K T ET AL, "THE PEPTIDE RECOGNIZED BY HLA-A68.2-RESTRICTED, SQUAMOUS CELL CARCINOMA OF THE LUNG-SPECIFIC CYTOTOXIC T LYMPHOCYTES IS DERIVED FROM A MUTATED ELONGATION FACTOR 2 GENE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19981115), vol. 58, no. 22, ISSN 0008-5472, pages 5144 - 5150, XP000946579 [A] 1-5 * the whole document *
by applicantJP2009002608
    - NYGARD 0; NILSSON L., "Kinetic determination of the effects of ADP-ribosylation on the interaction of eukaryotic elongation factor 2 with ribosomes", J BIOL CHEM., (1990), vol. 265, pages 6030 - 4
    - The Proteins, ACADEMIC PRESS INC., (1976), vol. 2
    - "Peptide Synthesis", Development of Medicine, Sequel, HIROKAWA SHOTEN CO., (1991), vol. 14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.